Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer

Mesenchymal epithelial transition (MET) receptor factor, the hepatocyte growth factor receptor, is a receptor tyrosine kinase that is overexpressed and activated in a subset of human epithelial malignancies. In this study, the clinical significance of mesenchymal epithelial transition protein and mRNA expression in invasive breast cancer tissues was investigated. A tissue microarray was constructed using tissues from 371 patients with invasive ductal cancer (IDC) who underwent radical tumor excision for breast cancer. The correlation between mesenchymal epithelial transition mRNA and protein expression were analyzed with mesenchymal epithelial transition immunohistochemistry (IHC) and RNAscope in situ hybridization (ISH). Positive immunohistochemistry results for mesenchymal epithelial transition protein were detected in 46 (13%) patients, and 45 (12%) patients exhibited high mesenchymal epithelial transition mRNA levels. High mesenchymal epithelial transition protein and high mesenchymal epithelial transition mRNA levels were significantly associated with high histologic grade, negative estrogen receptor (ER) status, and a high proliferation index in invasive ductal cancer. Kaplan-Meier analysis showed no significant association of either mesenchymal epithelial transition mRNA or protein expression with survival. There was, however, a significant correlation between mesenchymal epithelial transition mRNA expression and mesenchymal epithelial transition protein expression. The present study showed that mesenchymal epithelial transition mRNA and protein expression are significantly correlated and are important prognostic factors in invasive breast cancer.

Immunohistochemistry; In situ hybridization; Invasive ductal carcinoma; MET.

[1] Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al.: “GLOBOCAN2012 v 1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. [Internet]. Lyon, France: International Agency for Research on Cancer, 2013”.

[2] Kamangar F., Dores G.M., Anderson W.F.: “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world”. J. Clin. Oncol., 2006, 24, 2137.

[3] Yan S., Jiao X., Zou H., Li K.: “Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases”. Diagn. Pathol., 2015, 10, 62.

[4] Zhang Y., Xia M., Jin K., Wang S., Wei H., Fan C., et al.: “Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities”. Mol. Cancer, 2018, 17, 45.

[5] Ghoussoub R.A., Dillon D.A., D’Aquila T., Rimm E.B., Fearon E.R., Rimm D.L.: “Expression of c-met is a strong independent prognostic factor in breast carcinoma”. Cancer, 1998, 82, 1513.

[6] Hiscox S., Jordan N.J., Jiang W., Harper M., McClelland R., Smith C., et al.: “Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumourstroma interactions”. Endocr. Relat. Cancer, 2006, 13, 1085.

[7] Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C.: “Met receptor contributes to trastuzumab resistance of Her2- overexpressing breast cancer cells”. Cancer Res., 2008, 68, 1471.

[8] Tolgay Ocal I., Dolled-Filhart M., D’Aquila T.G., Camp R.L., Rimm D.L.: “Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors”. Cancer, 2003, 97, 1841.

[9] Lengyel E., Prechtel D., Resau J.H., Gauger K., Welk A., Lindemann K., et al.: “C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu”. Int. J. Cancer, 2005, 113, 678.

[10] Inanc M, Ozkan M., Karaca H., Berk V., Bozkurt O., Duran A.O., et al.: “Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer”. Med. Oncol., 2014, 31, 801.

[11] Zagouri F., Brandstetter A., Moussiolis D., Chrysikos D., Dimitrakakis C., Tsigginou A., et al.: “Low protein expression of MET in ER-positive and HER2-positive breast cancer”. Anticancer Res., 2014, 34, 1227.

[12] Gisterek I., Lata E., Halon A., Matkowski R., Szelachowska J., Biecek P., et al.: “Prognostic role of c-met expression in breast cancer patients”. Rep. Pract. Oncol. Radiother., 2011, 16, 173.

[13] Koh Y.W., Lee H.J., Ahn J.H., Lee J.W., Gong G.: “MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting”. Pathol. Res. Pract., 2014, 210, 494.

[14] Zhao X., Qu J., Hui Y., Zhang H., Sun Y., Liu X., et al.: “Clinico Pathological and prognostic significance of c-Met overexpression in breast cancer”. Oncotarget, 2017, 8, 56758.

[15] Wang F., Flanagan J., Su N., Wang L.C., Bui S., Nielson A., et al.: “RNAscope: a novel in situ RNA analysis platform for formalinfixed, paraffin-embedded tissues”. J. Mol. Diagn., 2012, 14, 22.

[16] Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al.: “American Joint Committee on Cancer: AJCC Cancer Staging Manual”. 6th ed, New York, NY, USA: Springer, 2002, 157.

[17] Kwak Y., Yun S., Nam S.K., Seo A.N., Lee K.S., Shin E., et al.: “Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer”. J. Transl. Med., 2017, 15, 167.

[18] Choi J., Lee H.E., Kim M.A., Jang B.G., Lee H.S., Kim W.H.: “Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization”. PLoS One, 2014, 9, 111658.

[19] Gromoslaw A.S., Raffaella S., Beth M., Gayatry M., Anne B., Heidi A., et al.: “Amplification of MET May Identify a Subset of Cancers with Extreme Sensitivity to the Selective Tyrosine Kinase Inhibitor PHA-665752”. Proc. Natl. Acad. Sci. U S A, 2006, 103, 231.

[20] Jeffrey A.E., Kreshnik Z., Tetsuya M., Youngchul S., Courtney H., Joon Oh P., et al.: “MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling”. Science, 2007, 316, 1039.

[21] Danilkovitch-Miagkova A., Zbar B.: “Dysregulation of Met receptor tyrosine kinase activity in invasive tumors”. J. Clin. Invest., 2002, 109, 863.

[22] Carracedo A., Egervari K., Salido M., Rojo F., Corominas J.M., Arumi M., et al.: “FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors”. Breast Cancer Res., 2009, 11, 402.

[23] Wang M., Liang L., Lei X., Multani A., Meric-Bernstam F., Tripathy D., et al.: “Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers”. Ann. Diagn. Pathol., 2018, 35, 69.

[24] Ponzo M.G., Lesurf R., Petkiewicz S., O’Malley F.P., Pinnaduwage D., Andrulis I.L., et al.: “Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer”. Proc. Natl. Acad. Sci. U S A, 2009, 106, 12903.

[25] Zagouri F., Bago-Horvath Z., Rossler F., Brandstetter A., Bartsch R., Papadimitriou C.A., et al.: “High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer”. Br. J. Cancer, 2013, 108, 1100.

[26] Gonzalez-Angulo A.M., Chen H., Karuturi M.S., ChavezMacGregor M., Tsavachidis S., Meric-Bernstam F., et al.: “Frequency of mesenchymal- epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer”. Cancer, 2013, 119, 7.